Dr Jayne Sutherland


of Immunology

MRC Unit, The Gambia at London School of Hygiene and Tropical Medicine
United Kingdom

+220 3170701

I have been permanently based in The Gambia since 2006; initially as a post-doc and now as head of the TB research group which consists of the TB case-contact (TBCC) cohort and the TB immunology laboratory. My PhD and early post-doctoral career were spent in Australia and London respectively with a focus on immunotherapy for cancer; I changed research objectives to infectious disease immunology when I moved to the MRC Unit, The Gambia (MRCG). The TBCC cohort is one of the longest running case-contact cohorts worldwide and provides a unique opportunity for multi- disciplinary research. It is run in close collaboration with the national TB program to promote health systems strengthening and public engagement. Underpinning all our studies is fundamental science to determine mechanisms, risk factors, and biomarkers/correlates of risk for TB infection and disease. Current research projects in my laboratory include elucidating the risk factors for long-term lung pathology in TB; defining the role of non-classical T cells, B cells and antibodies in the early response to Mtb infection; defining correlates of risk for progression to active TB; understanding immunity at the site of infection; immunity to TB in the context of HIV and other co-infections (including Influenza) and development of rapid diagnostic tests for TB.


Faculty of Infectious and Tropical Diseases
MRC - Gambia


TB Centre


I am deputy MO for DL MSc IDM213 immunology of Infection and Vaccines and a tutor for DL IDM 502 tuberculosis. I also lecture for MSc IID. 


The TB case-contact (TBCC) platform at the MRC Unit in The Gambia provides a unique opportunity to characterize immunity to Mycobacterium tuberculosis (Mtb) across the spectrum of infection and disease. This long-running platform (20 years) recruits index TB cases and their close contacts and aligns microbiology with epidemiological, clinical, and immunological evaluation. My main research focus includes biomarker discovery, impact of co-infections (including SARS-CoV-2) and diagnostic development. My research group are involved in several projects aimed at dissecting the key transition points in the Mtb life cycle and include both clinical and basic immunology studies. I also hold a patent on the use of host biomarkers in sputum for diagnosis of TB. We have excellent on-site facilities including sequencers, targeted RNA analyzers, three 18-colour flow cytometers and 2 new Bioplex 100/200 machines.

Current funding

The three major projects in my lab currently are:

1. TB Sequel II (2023-2028)

Funder: BMBF

Role: Site PI

Overview: This project is a multi-site study (Gambia, Mozambique, Tanzania, South Africa and involves understanding the pathogenesis and risk factors of long-term lung damage following TB treatment. Analysis now includes the impact of SARS-CoV-2 on pulmonary outcome.

2. ENDx-TB (2020-2025)

Funder: NIH

Role: Co-I

Overview: The aim of this project is to perform head-to-head comparison of novel TB diagnostics/prognostics with current gold-standard tests. This is a multi-site study (Gambia, South Africa, Vietnam) analysing child, adolescent and adult patients presenting with symptoms suggestive of TB but prior to microbiological confirmation. In addition, exposed household contacts will be recruited to determine the utility of point-of-care tests for detection of sub-clinical TB.

3. TBVAC-HORIZON (2023-2027)

Funder: European Union

Role: Co-PI

Overview: The aim of this project is to:

increase our understanding and develop tools pertaining to immune protection in the lung, the major site of tuberculosis infection. This knowledge will be exploited to develop mucosal strategies for translating towards clinical evaluation and
possible implementation. The interwoven activities will consolidate Europe’s leading role in TB vaccine research and innovation, with the ultimate goal of accelerated availability of affordable, accessible and more effective TB vaccines.

Research degree supervision

I currently have research degree students working on microbiological and immunological aspects of TB. I am interested in supervising research degree students working on clinical or immunological aspects of Tuberculosis including post-TB lung disease. 


Selected Publications

Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Mycobacterium tuberculosis Specific T Cell Activation and Functional Markers.
Vickers MA; Darboe F; Muefong CN; Mbayo G; Barry A; Gindeh A; Njie S; Riley A-J; Sarr B; Sambou B
Changes in Mycobacterium tuberculosis-Specific Immunity With Influenza co-infection at Time of TB Diagnosis.
Mendy J; Jarju S; Heslop R; Bojang AL; Kampmann B; Sutherland JS
Changes in Transcript, Metabolite, and Antibody Reactivity During the Early Protective Immune Response in Humans to Mycobacterium tuberculosis Infection.
Weiner J; Domaszewska T; Donkor S; Kaufmann SHE; Hill PC; Sutherland JS
Clinical infectious diseases
Functional and Phenotypic Changes of Natural Killer Cells in Whole Blood during Mycobacterium tuberculosis Infection and Disease.
Garand M; Goodier M; Owolabi O; Donkor S; Kampmann B; Sutherland JS
Frontiers in immunology
Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis.
Suliman S; Thompson EG; Sutherland J; Weiner J; Ota MOC; Shankar S; Penn-Nicholson A; Thiel B; Erasmus M; Maertzdorf J
American journal of respiratory and critical care medicine
Metabolite changes in blood predict the onset of tuberculosis.
Weiner J; Maertzdorf J; Sutherland JS; Duffy FJ; Thompson E; Suliman S; McEwen G; Thiel B; Parida SK; Zyla J
Nature Communications
IL-17 Production from T Helper 17, Mucosal-Associated Invariant T, and γδ Cells in Tuberculosis Infection and Disease.
Coulter F; Parrish A; Manning D; Kampmann B; Mendy J; Garand M; Lewinsohn DM; Riley EM; Sutherland JS
Frontiers in immunology
Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB.
Chegou NN; Sutherland JS; Malherbe S; Crampin AC; Corstjens PLAM; Geluk A; Mayanja-Kizza H; Loxton AG; van der Spuy G; Stanley K
A blood RNA signature for tuberculosis disease risk: a prospective cohort study.
Zak DE; Penn-Nicholson A; Scriba TJ; Thompson E; Suliman S; Amon LM; Mahomed H; Erasmus M; Whatney W; Hussey GD
Dysregulation of Apoptosis Is a Risk Factor for Tuberculosis Disease Progression.
Elliott TOJP; Owolabi O; Donkor S; Kampmann B; Hill PC; Ottenhoff THM; Haks MC; Kaufmann SHE; Maertzdorf J; Sutherland JS
The Journal of infectious diseases
Iron homeostasis and progression to pulmonary tuberculosis disease among household contacts.
Minchella PA; Donkor S; McDermid JM; Sutherland JS
Tuberculosis (Edinburgh, Scotland)
Rapid diagnosis of tuberculosis using ex vivo host biomarkers in sputum.
Ota MOC; Mendy JF; Donkor S; Togun T; Daramy M; Gomez MP; Chegou NN; Sillah AK; Owolabi O; Kampmann B
The European respiratory journal
Skewing of the CD4(+) T-cell pool toward monofunctional antigen-specific responses in patients with immune reconstitution inflammatory syndrome in The Gambia.
Wilson H; de Jong BC; Peterson K; Jaye A; Kampmann B; Ota MOC; Sutherland JS
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Highly accurate diagnosis of pleural tuberculosis by immunological analysis of the pleural effusion.
Sutherland JS; Garba D; Fombah AE; Mendy-Gomez A; Mendy FS; Antonio M; Townend J; Ideh RC; Corrah T; Ota MOC
Identification of probable early-onset biomarkers for tuberculosis disease progression.
Sutherland JS; Hill PC; Adetifa IM; de Jong BC; Donkor S; Joosten SA; Opmeer L; Haks MC; Ottenhoff THM; Adegbola RA
Polyfunctional CD4(+) and CD8(+) T cell responses to tuberculosis antigens in HIV-1-infected patients before and after anti-retroviral treatment.
Sutherland JS; Young JM; Peterson KL; Sanneh B; Whittle HC; Rowland-Jones SL; Adegbola RA; Jaye A; Ota MOC
Journal of immunology (Baltimore, Md. : 1950)
Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease.
Sutherland JS; Adetifa IM; Hill PC; Adegbola RA; Ota MOC
European journal of immunology
See more Publications